UNION CITY, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that David Young, Pharm.D., Ph.D., currently a member of Questcor’s Board of Directors, has been appointed to the newly created position of Chief Scientific Officer, and Sian E. Bigora, Pharm.D. has been appointed to the newly created position of Vice President Regulatory Affairs. Dr. Young (56) joins Questcor from AGI Therapeutics plc where he served as Executive Director & President, U.S. Operations for the specialty pharmaceutical company since 2006. Dr. Bigora also joins Questcor from AGI Therapeutics where she served as Vice President, Clinical Research and Regulatory Affairs since 2007. Both executives will be based in Questcor’s new East Coast offices in Columbia, Maryland. Dr. Young will resign from Questcor’s board effective on his start date as an employee of the Company.
